对状细胞疾病的全身药物和对状细胞视网膜病变的潜在应用
Anupam K Garg1, Adrienne W Scott
1Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Current opinion in ophthalmology
|March 11, 2024
概括
系统性药物,如氧尿素,有助于预防状细胞视网膜病变. 新的基因疗法对状细胞疾病 (SCD) 有希望,但它们对视网膜病变的影响需要进一步调查.
科学领域:
- 眼科医生 眼科 眼科
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 状细胞视网膜病是状细胞疾病 (SCD) 的严重并发症.
- 传统的全身疗法已证明在预防其发展方面具有有效性.
- 新兴的疾病修饰疗法为SCD提供了新的治疗途径.
研究的目的:
- 审查关于SCD全身药物的文献,以及它们在状细胞视网膜病变中的作用.
- 评估新型SCD疗法对视网膜病变预防的影响.
- 了解在血红蛋白SC (HbSC) 疾病中的视网膜病变的管理.
主要方法:
- 对系统性SCD治疗研究的文献综述.
- 对传统和新型治疗剂的数据分析.
- 关于状细胞视网膜病变的研究评估.
主要成果:
- 传统疗法,如氧尿素,降低了状细胞视网膜病变的风险.
- 新的基因疗法 (exa-cel, lovo-cel) 对SCD显示系统性益处,但视网膜病变的疗效尚不清楚.
- 获取有限和高成本阻碍了新型SCD疗法的使用.
- 系统治疗在HbSC疾病和视网膜病变中的作用尚不清楚.
结论:
- 基尿素仍然是SCD的关键治疗方法,可能降低视网膜病变的风险.
- 新的,潜在的治愈性SCD疗法的对视网膜病变的影响需要进行广泛的研究.
- 进一步的研究是必不可少的,以阐明新兴SCD治疗状细胞视网膜病变的含义.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
01:27Open Angle Glaucoma: Treatment
448
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
448